

## **Recombinant Rat IGF1**

Cat No:HR2R2268

For research use only

## Overview

Accession Post Alternative Name Solume Species Raises Source E. Grand Description Reg (2), IGF effet Functions Formulation Resolubility Appearance Lyoung Molecular Weight Purity >98	482 8025 matomedin, Insulin-like growth factor I, IGF-I, Igf1 Recombinant Rat Insulin-Like Growth Factor (IGF1)
Accession Policy Alternative Name Solution Reservation	matomedin, Insulin-like growth factor I, IGF-I, Igf1 recombinant Rat Insulin-Like Growth Factor (IGF1)  t  coli  culin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is cucturally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa sture IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C- terminal gions. Mature human IGF-I shares 94% and 96% as sequence identity with mouse and rat IGF-I, respectively and exhibits cross-species activity. It shares 64% as sequence identity with mature human IGF-II. Circulating F-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine
Alternative Name  Solume  Species  Rai  Source  E. G  Ins stru C ma reg (2): IGF effe  Functions  Formulation  Rei  Solubility  Appearance  Lyc  Molecular Weight  Purity  Sol	matomedin, Insulin-like growth factor I, IGF-I, Igf1 roli  culin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is ucturally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa ature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C- terminal gions. Mature human IGF-I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively and exhibits cross-species activity. It shares 64% aa sequence identity with mature human IGF-II. Circulating F-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine
Name  Species  Rai  Species  Rai  Source  E. 6  Ins structions  Functions  Formulation  Rei  Solubility  Appearance  Lyc  Molecular Weight  Purity  Solid  Purity  Solid  Rai  Lyc  Rai  L	coli  sulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is ucturally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa ature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C- terminal gions. Mature human IGF-I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively , and exhibits cross-species activity. It shares 64% aa sequence identity with mature human IGF-II. Circulating F-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine
Source E. c Ins structions  Punctions  Formulation  Solubility  Appearance  Molecular Weight  Purity  Source  Ins structions  Froma reg (2), IGF effe effe effe effe effe effe effe ef	coli  sulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is ucturally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa ature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C- terminal gions. Mature human IGF-I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively , and exhibits cross-species activity. It shares 64% aa sequence identity with mature human IGF-II. Circulating F-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine
Description  Ins stru C-ma reg (2). IGF effe  Functions  Formulation  Ref  Solubility  Appearance  Lyc  Molecular Weight  Purity  Purity  Ins stru C-ma reg (2). Ins reg (2).	sulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is ucturally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa ature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C- terminal gions. Mature human IGF-I shares 94% and 96% as sequence identity with mouse and rat IGF-I, respectively, and exhibits cross-species activity. It shares 64% as sequence identity with mature human IGF-II. Circulating F-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine
Description reg (2). IGF effect (2). IGF effec	ature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C- terminal gions. Mature human IGF-I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively, and exhibits cross-species activity. It shares 64% aa sequence identity with mature human IGF-II. Circulating F-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine
Functions specification specif	
Solubility  A consolidation of solidation of	e ED(50) was determined by a cell proliferation assay using FDC-P1 cells is ? 1.0 ng/mL, corresponding to a ecific activity of ? 1.0 x 10^6 units/mg.
Appearance Lyc  Molecular Weight 8  Purity >98	combinant Rat IGF1 was lyophilized from a 0.2 ?m filtered PBS solution, pH 7.4.
Molecular Weight  8  Purity >98	quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This ution can then be diluted into other buffers.
Weight 8  Purity >98	ophilized Powder
Concentration <1.	5% as determined by SDS-PAGE
	.0 EU/?g of recombinant protein as determined by the LAL method.
Shipping Am Condition	nbient Temperature
Storage	e lyophilized protein is stable for at least one year from date of receipt at -70?C. Upon reconstitution, this tokine can be stored in working aliquots at 2? - 8?C for one month, or at -20?C for six months, with a carrier of the protein without detectable loss of activity. Avoid repeated freeze/thaw cycles

<del>info@bioelsa.co</del>m